Sep 28 2023 52 mins
In a new episode of The Onco’Zine Brief, Peter Hofland talks with Jeffery Auletta, MD is Senior Vice President, Patient Outcomes and Experience, National Marrow Donor Program® (NMDP)/Be The Match®.
Be The Match® is a global leader in bone marrow transplantation. The organization conducts research to improve transplant outcomes provide support and resources for patients, and partner with a global network.
Unmet medical need
Every three or four minutes, someone in the United States is diagnosed with a hematological malignancy such as leukemia, a cancer of blood-forming tissues, including bone marrow.
For many patients, their only hope for a cure is a stem cell transplant. In the program, Hofland and Auletta talk about these unmet medical needs and about the new developments exploring the use of a standardized method of assessing measurable residual disease (MRD) before allogeneic hematopoietic stem cell transplantation (HCT) in patients with leukemia and how this provides valuable insight into MRD as a predictive tool to inform HCT decisions and individualize treatment to improve outcomes.
Hofland and Auletta also talk about the importance of people to join and register with Be The Match® as a bone marrow donor to bring hope to people in need.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit our Patreon page, or contact the sales team.
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.
The Onco’Zine Brief is made possible, in part, by Java Original Coffee and Roastmasterz by Java Original Coffee.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.
Be The Match® is a global leader in bone marrow transplantation. The organization conducts research to improve transplant outcomes provide support and resources for patients, and partner with a global network.
Unmet medical need
Every three or four minutes, someone in the United States is diagnosed with a hematological malignancy such as leukemia, a cancer of blood-forming tissues, including bone marrow.
For many patients, their only hope for a cure is a stem cell transplant. In the program, Hofland and Auletta talk about these unmet medical needs and about the new developments exploring the use of a standardized method of assessing measurable residual disease (MRD) before allogeneic hematopoietic stem cell transplantation (HCT) in patients with leukemia and how this provides valuable insight into MRD as a predictive tool to inform HCT decisions and individualize treatment to improve outcomes.
Hofland and Auletta also talk about the importance of people to join and register with Be The Match® as a bone marrow donor to bring hope to people in need.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit our Patreon page, or contact the sales team.
To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.
The Onco’Zine Brief is made possible, in part, by Java Original Coffee and Roastmasterz by Java Original Coffee.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.